Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05766748 · ClinicalTrials.gov registry record · Phase 1

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer

A Phase 1 study of Metastatic Pancreatic Cancer, sponsored by Cantex Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
6
Study locations

NCT05766748 is a Phase 1 study of Metastatic Pancreatic Cancer that is actively recruiting participants, run by Cantex Pharmaceuticals. The registered enrollment target is 30 participants, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05766748, a Phase 1 study of Metastatic Pancreatic Cancer, is actively recruiting participants, sponsored by Cantex Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.

Conditions Studied

Metastatic Pancreatic Cancer

Interventions

  • DRUG Azeliragon

Study Locations (6)

California

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute - Los Angeles

Florida

  • Boca Raton Regional Hospital, Lynn Cancer Institute - Boca Raton

Oregon

  • Williamette Valley Cancer Institute and Research Center - Eugene

Pennsylvania

  • AHN Cancer Institute - Allegheny General Hospital - Pittsburgh

South Carolina

  • Prisma Health - Upstate - Greenville

Texas

  • Texas Oncology - Northeast Texas - Tyler

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-06-01
Est. Completion 2025-05
Phase Phase 1

Sponsor

Cantex Pharmaceuticals

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05766748

The ClinicalTrials.gov registry entry for NCT05766748 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 32 other Metastatic Pancreatic Cancer trials with a reported enrollment target (72% lower). The listed sponsor is Cantex Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Azeliragon is the first listed.

NCT05766748 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Oregon.

Frequently Asked Questions

What is clinical trial NCT05766748 about?

NCT05766748 is a clinical study titled "Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer". This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.

What is the current status of trial NCT05766748?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-01. Estimated completion is 2025-05.

What conditions does trial NCT05766748 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Cancer.

What interventions are being tested in trial NCT05766748?

The interventions under investigation include: Azeliragon (DRUG).

Who is sponsoring clinical trial NCT05766748?

This trial is sponsored by Cantex Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05766748 being conducted?

This trial has 6 study locations across California, Florida, Oregon, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Pancreatic Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.